Incyte Aktie
WKN: 896133 / ISIN: US45337C1027
23.04.2024 14:14:37
|
Incyte To Buy Privately Held Escient Pharma
(RTTNews) - Incyte Corp. (INCY) announced Tuesday its agreement to acquire Escient Pharmaceuticals and its assets for $750 million plus its net cash remaining at the deal closure, subject to customary adjustments.
The acquisition is subject to clearance under the Hart-Scott-Rodino Act, among other customary conditions. The deal will become effective promptly following the satisfaction or waiver of these conditions which is currently anticipated to be by the third quarter of 2024.
Incyte said the acquisition will include EP262, a first-in-class, potent, highly selective, once-daily small molecule antagonist of Mas-related G protein-coupled receptor X2 or MRGPRX2, and EP547, a first-in-class oral MRGPRX4 antagonist.
Herve Hoppenot, Chief Executive Officer, Incyte, said, "This acquisition builds on our strategy to develop differentiated and first-in-class medicines with high potential. EP262 and EP547 are complementary additions to our portfolio, providing an opportunity to leverage our expertise, address the needs of patients with inflammatory diseases and additional potential launch opportunities starting in 2029."
In the deal, Centerview Partners LLC and Goldman Sachs & Co. LLC advised Escient and Fenwick & West LLP acted as legal counsel, while Covington & Burling LLP acted as legal counsel for Incyte.
In pre-market activity on the Nasdaq, Incyte shares were gaining around 1.3 percent to trade at $52.60.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Incyte Corp.mehr Nachrichten
21.03.25 |
Schwache Performance in New York: So entwickelt sich der S&P 500 am Freitagnachmittag (finanzen.at) | |
21.03.25 |
Anleger in New York halten sich zurück: S&P 500 zeigt sich leichter (finanzen.at) | |
20.03.25 |
S&P 500-Wert Incyte-Aktie: So viel Verlust hätte eine Incyte-Investition von vor 5 Jahren eingebracht (finanzen.at) | |
17.03.25 |
S&P 500 aktuell: S&P 500 zum Ende des Montagshandels mit grünem Vorzeichen (finanzen.at) | |
17.03.25 |
Montagshandel in New York: S&P 500 notiert nachmittags im Plus (finanzen.at) | |
17.03.25 |
Freundlicher Handel in New York: S&P 500 mit grünem Vorzeichen (finanzen.at) | |
17.03.25 |
Gute Stimmung in New York: S&P 500-Anleger greifen zum Start des Montagshandels zu (finanzen.at) | |
13.03.25 |
S&P 500-Titel Incyte-Aktie: So viel Verlust wäre bei einem Investment in Incyte von vor 3 Jahren angefallen (finanzen.at) |
Analysen zu Incyte Corp.mehr Analysen
Aktien in diesem Artikel
Incyte Corp. | 57,56 | 0,45% |
|